DiaMedica Therapeutics posted Earnings Per Share of $-0.19 for the quarter, narrowly beating the consensus estimate of $-0.20 while ending with $43.5 million in cash. The outperformance and ample cash runway into 2027 reassure investors that the firm can continue advancing its preeclampsia and stroke programs without immediate dilution.

Key Highlights

  • Cash $43.5M sustains runway through 2027 despite a $10.1M quarterly loss
  • Phase 2 preeclampsia trial showed mean SBP drop of 29.1 mmHg and DBP drop of 17.0 mmHg
  • Stroke ReMEDy2 trial enrollment exceeds 85% with interim readout slated for Q1 2027

DiaMedica Therapeutics (NASDAQ: DMAC) reported earnings per share of $-0.19 for the quarter ended June 30, 2026, edging the consensus forecast of $-0.20. The company also disclosed a cash balance of $43.5 million, a figure that supports a projected runway through 2027.

EPS Beats Consensus

The earnings release highlighted a modest improvement over analyst expectations, with EPS of $-0.19 versus the predicted $-0.20. Net loss widened to $10.1 million for the quarter, up from $7.7 million a year earlier, while six‑month losses grew to $20.2 million from $15.4 million. Research and Development expenditures climbed to $8.2 million, reflecting the scaling of multiple trial programs.

Although the loss widened, the EPS beat signals tighter cost management relative to Revenue expectations, suggesting the firm is managing its growth trajectory more efficiently than peers.

Cash Position Fuels Clinical Pipeline

DiaMedica’s cash, cash equivalents and short‑term investments fell to $43.5 million from $59.9 million at the end of 2025, while current liabilities rose to $6.6 million from $5.1 million, leaving Working Capital at $37.7 million. The reduction in cash reflects higher operating outlays, yet the balance remains sufficient to finance ongoing Phase 2 studies and the global expansion of the ReMEDy2 stroke trial. With a burn of $17.2 million in operating cash during the first half of 2026, the company expects its Liquidity to sustain operations without seeking immediate external financing, allowing it to avoid share dilution that could pressure the stock price.

Clinical Advances Signal Growth Potential

In the Phase 2 preeclampsia Part 1a cohort, DM199 produced a mean systolic blood‑pressure reduction of 29.1 mmHg from a baseline of 169.3 mmHg and a diastolic decline of 17.0 mmHg from 103.7 mmHg, both statistically significant (p < 0.001). These results were maintained below 160 mmHg over 24 hours (p < 0.01). The company also completed enrollment of the first cohort in its early‑onset fetal growth restriction trial, enrolling six participants at the 5 µg/kg dose.

Meanwhile, the ReMEDy2 acute ischemic stroke trial surpassed 85% of its 200‑patient target, positioning it for an interim analysis in Q1 2027. These data points collectively reinforce the therapeutic promise of DM199 across multiple ischemic indications.

Upcoming Data Releases and Outlook

DiaMedica’s stock rallied modestly on the day, with peers IPSC and LXEO flat and PALI down 2.2%, while short interest stood at 9% of shares outstanding and required 21.2 days to cover. The company held a conference call on August 11, 2026, outlining its financial and clinical progress. The forthcoming interim analysis of the ReMEDy2 trial in early 2027 will further clarify the stroke program’s trajectory, offering investors a near‑term catalyst that could reshape valuation assumptions.

Peers Moving on This News

  • Century Therapeutics Inc (IPSC) little changed
  • Lexeo Therapeutics Inc (LXEO) little changed
  • Palisade Bio Inc (PALI) down 2.2%

Analysis based on the Form 8-K filed 10 August 2026; figures verified against the filing and live market data.

This article is for informational purposes only and does not constitute financial advice. Please consult a licensed financial adviser before making Investment decisions.